Business context and reporting period
Entity discrepancy: The request identifies TALPHERA, INC., but the supplied filing is AcelRx Pharmaceuticals, Inc.’s Form 10-K. This summary covers AcelRx’s fiscal year ended December 31, 2021, not a standalone 2021 fourth quarter.
AcelRx develops and commercializes therapies for medically supervised settings. Its marketed products include DSUVIA in the U.S. and DZUVEO in Europe; its pipeline includes Zalviso, ephedrine and phenylephrine pre-filled syringes, and nafamostat candidates Niyad and LTX-608.
Financial performance and position
| Metric | 2021 | 2020 |
|---|---|---|
| Total revenue | $2.8 million | $5.4 million |
| Product sales | $1.0 million | $2.5 million |
| Operating loss | $36.0 million | $41.0 million |
| Net loss | $35.1 million | $40.4 million |
| Net loss per share | $0.29 | $0.47 |
| Cash used in operations | $30.0 million | $38.5 million |
- Product revenue fell 60% year over year: DSUVIA sales declined 48% to $0.7 million, while Zalviso sales declined 76% to $0.3 million.
- Gross loss was approximately $2.7 million (revenue less cost of goods sold of $3.8 million); gross margin was approximately negative 33%.
- Research and development expense was $4.1 million, up 2%; selling, general and administrative expense was $30.9 million, down 15%.
- At year-end, cash and cash equivalents were $12.7 million and short-term investments were $39.0 million, totaling $51.6 million. Current assets were $55.5 million versus current liabilities of $18.5 million.
- Oxford debt outstanding was $13.3 million, including $8.8 million classified as current; scheduled maturity is June 2023. Separately, the liability for sold future Zalviso royalties was $85.3 million.
- Stockholders’ deficit was $35.9 million. Shares outstanding increased to 136.8 million at year-end from 98.8 million a year earlier.
Material changes versus the prior year
- Revenue declined mainly because 2020 included a significant U.S. Department of Defense order and because Grunenthal’s Zalviso commercialization ended in May 2021.
- Operating loss narrowed by about $5.0 million, principally reflecting lower SG&A; net loss improved by about $5.3 million.
- Cash and investments rose from $42.9 million to $51.6 million, largely due to equity financings. Financing cash flow was $41.5 million, while operating activities used $30.0 million.
- Aguettant received exclusive European DZUVEO rights in July 2021; AcelRx recognized $1.7 million of the approximately $2.9 million upfront payment as revenue. European DZUVEO sales had not begun by year-end.
- Grunenthal’s Zalviso rights reverted to AcelRx in May 2021. AcelRx remains obligated to seek a replacement license under its royalty monetization arrangement.
Outlook, risks and unusual items
- Management said existing capital resources were expected to fund operations for at least 12 months from the filing date, while warning that they would not fund operations indefinitely. The company expected significant losses to continue in 2022 and may need additional capital.
- Management expected near-term sales to remain pressured by COVID-related limits on access to healthcare facilities, delayed procedures and formulary reviews. The automated DSUVIA packaging line was installed, but FDA approval was then expected in the first half of 2023; management anticipated lower cost of goods sold once operational.
- The Zalviso U.S. NDA had not been resubmitted. Timing depends partly on FDA opioid-review guidance; further FDA requirements or concerns about device errors and inadvertently dropped tablets could delay or prevent approval.
- DSUVIA is subject to a restricted-distribution REMS. In February 2021, FDA issued a promotional-material Warning Letter. AcelRx reported updating materials and said FDA was preparing a close-out letter, but it had not received one as of the filing.
- Key risks include continued losses and financing needs, opioid regulation and reputational exposure, reliance on single-source suppliers, reimbursement and adoption uncertainty, and litigation. A securities class action and consolidated shareholder derivative actions were pending; the company said it could not estimate a reasonably possible loss.
- On January 7, 2022, after year-end, AcelRx acquired Lowell Therapeutics for approximately $32.5 million plus adjustments, with up to approximately $26 million of contingent consideration. The acquisition included Niyad and LTX-608 assets.
- Nasdaq had notified AcelRx in December 2021 that its share price had failed the $1 minimum bid-price requirement; the initial compliance period ran through May 31, 2022.
Important facts for investors to verify
- Confirm that AcelRx, rather than TALPHERA, is the intended issuer and review the complete audited statements and notes.
- Track DSUVIA sales, U.S. customer access and DoD orders, as well as whether Aguettant launches DZUVEO and achieves commercial milestones.
- Monitor cash burn, financing activity, share dilution, debt payments and Oxford’s $5 million minimum unrestricted-cash covenant.
- Check the status of the Zalviso NDA, the FDA Warning Letter close-out, and qualification and approval of the automated packaging line.
- Review developments in the Lowell acquisition, pending litigation, Nasdaq listing compliance and the search for a Zalviso European partner.